Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer

IMPORTANCE: The 2017 international PACIFIC trial established a role for immunotherapy after chemoradiation for unresectable stage III non–small cell lung cancer (NSCLC). However, in the US, patients with NSCLC commonly differ from clinical trial populations in terms of age, health, access to care, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichert, Matthew D., Canavan, Maureen E., Maduka, Richard C., Li, Andrew X., Ermer, Theresa, Zhan, Peter L., Kaminski, Michael, Udelsman, Brooks V., Blasberg, Justin D., Park, Henry S., Goldberg, Sarah B., Boffa, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353596/
https://www.ncbi.nlm.nih.gov/pubmed/35925606
http://dx.doi.org/10.1001/jamanetworkopen.2022.24478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353596/
https://www.ncbi.nlm.nih.gov/pubmed/35925606
http://dx.doi.org/10.1001/jamanetworkopen.2022.24478

Ejemplares similares